Document is current
Any future updates will be listed below
-
Authors
Lowe, Michael https://orcid.org/0000-0001-5712-3800
Berman, Gabriele https://orcid.org/0009-0008-3390-9508
Labella Álvarez, Fernando
Sinclair, Alex https://orcid.org/0000-0003-2777-5132
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
- License Information
-
More Information
Article History
Received: 8 July 2025
Revised: 29 July 2025
Accepted: 27 August 2025
First Online: 18 September 2025
Competing interests
: Susan Mollan reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular Therapeutix); speaker fees (Teva); Travel (AbbVie and European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). Susan Mollan is a section editor at Eye Journal. Alex Sinclair reports consultancy fees from Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva UK and Novartis. She was previously a Director and Chief Scientific Officer with shares at Invex Therapeutics. Michael Lowe reports speaker fees (Pfizer); travel (AbbVie, Lundbeck, Teva). Authors declare no other financial relationships with any organisations that might have an interest in the submitted work; and no other relationships or activities that could appear to have influenced the submitted work.
